Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 4/20 | 0.37 |
| ▸ | TET3 | O43151 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | FBXL19 | Q6PCT2 | 3/20 | 0.35 |
| ▸ | CXXC5 | Q7LFL8 | 3/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.35 |
| ▸ | CXXC4 | Q9H2H0 | 3/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.35 |
| ▸ | TET1 | Q8NFU7 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21184123 | 0.89 | KMT2A (0.38) | KRASTET3KMT2AFBXL19CXXC5 | |
| SCHEMBL24090427 | 0.88 | HIF1A (0.34) | KMT2A | |
| SCHEMBL25804391 | 0.86 | CTSS (0.34) | — | |
| SCHEMBL30354217 | 0.86 | RXFP1 (0.35) | — | |
| SCHEMBL21183978 | 0.85 | KMT2A (0.37) | KRASTET3KMT2AFBXL19CXXC5 | |
| SCHEMBL21183980 | 0.83 | KRAS (0.40) | KRASTET3KMT2AFBXL19CXXC5 | |
| SCHEMBL21177633 | 0.83 | MEN1 (0.43) | KMT2A | |
| SCHEMBL21177967 | 0.82 | CCR2 (0.37) | KRASTET3KMT2AFBXL19CXXC5 | |
| SCHEMBL25804233 | 0.78 | GPR183 (0.37) | KMT2A | |
| SCHEMBL21180356 | 0.77 | GPR183 (0.35) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE ONCOLOGY LTD (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE ONCOLOGY LTD (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20210379055-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-12-09 | — | — | US | disclosed |
| WO-2019142126-A1 | SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | MCL1, ROS1, MKI67 | KRAS 24/4885TET3 3097/4885KMT2A 2821/4885 |
| US-20210379055-A1 | Substituted Alkynylene Compounds As Anticancer Agents | MCL1, ROS1, MKI67 | KRAS 24/4885TET3 3097/4885KMT2A 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.